Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Renal cell carcinoma treatment
TopicLeading institutions, researchers & key papers
This cluster of papers represents a comprehensive exploration of advancements in the research and treatment of renal cell carcinoma, including studies on various treatment modalities, prognostic factors, molecular characterization, nephron-sparing surgery, immunotherapy, genetic mutations, and clinical guidelines.
91,454
Works
1,173,462
Citations
IDs:OpenAlex
How has Renal cell carcinoma treatment's publication output changed over time?
ScholarIQpublication output · 2015–2019
Output grew0% over the shown period — from 1 works in 2015 to 1 in 2019.
1
1
1
201520182019
Who are the most-cited researchers behind Renal cell carcinoma treatment?
ScholarIQtop researchers by citations
What are the most-cited papers on Renal cell carcinoma treatment?
ScholarIQmost cited works
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer, Bernard Escudier, Ray McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Toni K. Choueiri, Howard Gurney, Frede Donskov, Petri Bono, John Wagstaff, Thomas Gauler, Takeshi Ueda, Yoshihiko Tomita, Fabio A.B. Schutz, Christian Kollmannsberger, James Larkin, Alain Ravaud, Jason S. Simon, Li-An Xu, Ian M. Waxman, Padmanee Sharma
New England Journal of Medicine. 20155,914 CitationsOPEN ACCESS
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J. Motzer, Nizar M. Tannir, Ray McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Toni K. Choueiri, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Victoria Neiman, Christian Kollmannsberger, Pamela Salman, Howard Gurney, Robert D. Hawkins, Alain Ravaud, Marc‐Oliver Grimm, Sergio Bracarda, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Brian I. Rini, Allen C. Chen, Sabeen Mekan, M. Brent McHenry, Megan Wind‐Rotolo, Justin Doan, Padmanee Sharma, Hans J. Hammers, Bernard Escudier
New England Journal of Medicine. 20184,676 CitationsOPEN ACCESS
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini, Elizabeth R. Plimack, V.P. Stus, Rustem Gafanov, Robert D. Hawkins, Dmitry Nosov, Frédéric Pouliot, B. Yа. Alekseev, Denis Soulières, Bohuslav Melichar, Ihor Vynnychenko, Anna Kryzhanivska, Igor Bondarenko, Sérgio Jobim Azevedo, Delphine Borchiellini, Cezary Szczylik, Maurice Markus, Raymond S. McDermott, Jens Bedke, Sophie Tartas, Yen‐Hwa Chang, Satoshi Tamada, Qiong Shou, Rodolfo F. Perini, Mei Chen, Michael B. Atkins, Thomas Powles
New England Journal of Medicine. 20193,428 CitationsOPEN ACCESS
Where is Renal cell carcinoma treatment research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Renal cell carcinoma treatment is open access?
ScholarIQopen access share
100%OPEN ACCESS
Gold
0%
Green
0%
Hybrid
0%
Bronze
100%
Closed
0%
Who collaborates most closely around Renal cell carcinoma treatment?
ScholarIQco-authorship network
United States
58%
France
17%
Canada
8%
United Kingdom
8%
Australia
8%